HK1123213A1 - Reduction of dizziness, a side effect associated with pirfenidone therapy - Google Patents

Reduction of dizziness, a side effect associated with pirfenidone therapy

Info

Publication number
HK1123213A1
HK1123213A1 HK09101727.9A HK09101727A HK1123213A1 HK 1123213 A1 HK1123213 A1 HK 1123213A1 HK 09101727 A HK09101727 A HK 09101727A HK 1123213 A1 HK1123213 A1 HK 1123213A1
Authority
HK
Hong Kong
Prior art keywords
dizziness
reduction
side effect
pirfenidone
effect associated
Prior art date
Application number
HK09101727.9A
Other languages
English (en)
Inventor
Cynthia Y Robinson
Jeffery Stuart Loutit
Michelle M Freemer
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1123213(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of HK1123213A1 publication Critical patent/HK1123213A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
HK09101727.9A 2005-12-02 2009-02-24 Reduction of dizziness, a side effect associated with pirfenidone therapy HK1123213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
PCT/US2006/045750 WO2007064738A1 (fr) 2005-12-02 2006-11-29 Procedes de reduction des effets indesirables associes a une therapie par la pirfenidone

Publications (1)

Publication Number Publication Date
HK1123213A1 true HK1123213A1 (en) 2009-06-12

Family

ID=37807840

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09101727.9A HK1123213A1 (en) 2005-12-02 2009-02-24 Reduction of dizziness, a side effect associated with pirfenidone therapy
HK11105855.0A HK1151726A1 (zh) 2005-12-02 2009-02-24 減少與吡非尼酮治療相關的副作用頭暈

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11105855.0A HK1151726A1 (zh) 2005-12-02 2009-02-24 減少與吡非尼酮治療相關的副作用頭暈

Country Status (14)

Country Link
US (1) US20070203202A1 (fr)
EP (2) EP2316453B1 (fr)
JP (3) JP5175740B2 (fr)
AT (1) ATE497766T1 (fr)
CA (1) CA2631646C (fr)
CY (1) CY1111355T1 (fr)
DE (1) DE602006020070D1 (fr)
DK (1) DK1965797T3 (fr)
ES (2) ES2385935T3 (fr)
HK (2) HK1123213A1 (fr)
PL (1) PL1965797T3 (fr)
PT (1) PT1965797E (fr)
SI (1) SI1965797T1 (fr)
WO (1) WO2007064738A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
EP2338489B1 (fr) 2006-12-18 2016-04-27 InterMune, Inc. Procédé permettant d'administrer une thérapie par le pirfenidone à un patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
JP2012515800A (ja) * 2009-01-26 2012-07-12 インターミューン， インコーポレイテッド 急性心筋梗塞および関連障害を処置するための方法
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP4059499A1 (fr) 2011-01-31 2022-09-21 Avalyn Pharma Inc. Composés analogues de pyridone et de pirfénidone en aérosol, et leurs utilisations
JP2014507474A (ja) * 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN103917223B (zh) * 2011-09-14 2017-08-08 盐野义制药株式会社 供吸入的药用组合物
CA2819967C (fr) 2012-08-31 2016-03-22 Intermune, Inc. Utilisation de pirfenidone en simultanee avec du ciprofloxacin
WO2014151517A1 (fr) 2013-03-15 2014-09-25 Intermune, Inc. Méthodes d'amélioration de l'intégrité microvasculaire
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (fr) * 2019-11-27 2021-06-03 塩野義製薬株式会社 Médicament destiné à réduire les effets secondaires de la pirfénidone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
JP4077320B2 (ja) * 2001-01-29 2008-04-16 塩野義製薬株式会社 ５−メチル−１−フェニル−２−（１ｈ）−ピリドンを有効成分として含有する医薬製剤
WO2004110245A2 (fr) * 2003-05-16 2004-12-23 Intermune, Inc. Polytherapie destinee au traitement du cancer
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Also Published As

Publication number Publication date
ES2385935T3 (es) 2012-08-03
DE602006020070D1 (de) 2011-03-24
ES2565190T3 (es) 2016-04-01
PL1965797T3 (pl) 2011-07-29
JP2012229275A (ja) 2012-11-22
EP1965797B1 (fr) 2011-02-09
HK1151726A1 (zh) 2012-02-10
CA2631646A1 (fr) 2007-06-07
EP2316453A1 (fr) 2011-05-04
JP5175740B2 (ja) 2013-04-03
ATE497766T1 (de) 2011-02-15
JP2009518293A (ja) 2009-05-07
DK1965797T3 (da) 2011-05-02
WO2007064738A1 (fr) 2007-06-07
EP1965797A1 (fr) 2008-09-10
CA2631646C (fr) 2016-07-26
CY1111355T1 (el) 2015-08-05
SI1965797T1 (sl) 2011-03-31
EP2316453B1 (fr) 2016-01-06
PT1965797E (pt) 2011-05-12
JP2015061888A (ja) 2015-04-02
US20070203202A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
HK1123213A1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
WO2007012022A3 (fr) Forme posologique unitaire renfermant un melange d'ibuprofene et de famotidine
WO2009002867A3 (fr) Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
WO2005081742A3 (fr) Formulations de dosages oraux de testostérone et procédés associés
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2005070930A3 (fr) Composes de tetrahydrocarboline comme agents anticancereux
WO2004075832A3 (fr) Methodes et compositions de traitement de douleurs chroniques au moyen de la dhea et de derives de celle-ci
WO2007018588A8 (fr) Composition pharmaceutique stable comprenant la forme iv de linézolide
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
WO2006084139A8 (fr) Dispositif implantable pour administration en continu d'interferon
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
CA2404387A1 (fr) Compositions de theanine favorisant le sommeil
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
TNSN07474A1 (en) Dosage regimen for prasugrel
WO2008091704A3 (fr) Traitement du syndrome de cushing et de l'autisme
WO2005120518A3 (fr) Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
EP1033133A4 (fr) Composition pour le traitement du diabete et procede de traitement du diabete
WO2007144889A3 (fr) Traitement de neurofibromatose
MX2007012991A (es) Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
HK1084879A1 (en) Use of a pharmaceutical composition to prepare the medicament for increasing therapeutic gain in radiotherapy and chemotherapy
WO2007067753A3 (fr) Méthodes pour réduire les effets secondaires dus au traitement du cancer
HK1083199A1 (en) A pharmaceutical composition for use in the prevention and/or treatment of the oral cavity diseases caused by microorganisms